European Cytokine Network

, Volume 27, Issue 4, pp 97–101 | Cite as

Effect of atorvastatin on interleukins and prostaglandin E2 in the kidney of type 1 diabetic rats

  • Anwar D. Maraqa
Research Article



The aim of the study was to evaluate a possible effect of atorvastatin on renal interleukins (ILs) and prostaglandin E2 (PGE2) in type 1 diabetic rats.


Thirty-two male rats from a local Wisterderived strain were included in this prospective study and were classified into four groups. Each group consisted of eight animals: Group 1, non-diabetic negative controls; Group 2, diabetic positive controls; Group 3, non-diabetic rats receiving atorvastatin for 4 weeks; and Group 4, diabetic rats receiving atorvastatin for 4 weeks. At the end of the designated period, the animals were sacrificed by cervical dislocation, and the kidneys were excised and homogenized to determine the level of IL-1β, IL-6, IL-10, and PGE2. The study duration was from June 2015 to May 2016 at Al-Ahlyya Amman University, Amman, Jordan.


In the kidneys of rats with streptozotocin-induced diabets, the levels of cytokines IL-1β, IL-6, IL-10, and PGE2 were significantly elevated above those of the control group. This clearly showed a detrimental effect of diabetes on the kidney. Treatment of diabetic rats with atorvastatin caused a decrease in all evaluated cytokines to levels near control values.


Our data suggest that atorvastatin has the potential to protect or attenuate diabetes-induced renal injury. However, the possible protective effect of atorvastatin should be supported by clinical evidence.

Key words

cytokines prostaglandin atorvastatin interleukin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Cerello A. Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Curr Opin Lipidol 2006; 17: 510–8.CrossRefGoogle Scholar
  3. 3.
    Shelton RJ, Velavan P, Nikitia NP, et al. Clinical trials update from the American Heart Association meeting: ACORN-CSD primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMENI, vitamin E meta-analysis, ESCAPE, CARP and SCD-HeFT cost-effectiveness study. Eur J Heart Fail 2005; 7: 127–35.CrossRefPubMedGoogle Scholar
  4. 4.
    Rovin BH, Dickerson JA, Tan LC, Fassler J. Modulation of IL-1-induced chemokine expression in human mesangial cells through alterations in redox status. Cytokine 1997; 9: 178–86.CrossRefPubMedGoogle Scholar
  5. 5.
    Pena LR, Hill BB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. J Parenter Enteral Nutr 1999; 23: 1–6.CrossRefGoogle Scholar
  6. 6.
    Donate-Correa J, Martín-Nú˜nez E, Muros-de-Fuentes M, Mora-Fernández C, and Navarro-González J. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res 2015; Article ID 948417:9.Google Scholar
  7. 7.
    Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci 2009; 116: 479–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Hasegawa G, Nakano K, Sawada M, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Sassy-Prigent C, Heudes D, Mandet C, et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000; 49: 466–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006; 26: 562-L 570.CrossRefPubMedGoogle Scholar
  12. 12.
    Bełtowski J, Atanassova P, Chaldakov GN, Jamroz-Wi´sniewska A, Kula W, Rusek M. Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites. Atherosclerosis 2011; 219: 526–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Mason RP, Corbalan JJ, Jacob RF, Dawoud H, Malinski T. Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes. J Physiol Pharmacol 2015; 66: 65–72.PubMedGoogle Scholar
  14. 14.
    Güc¸lü F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004; 58: 614–8.CrossRefGoogle Scholar
  15. 15.
    Okada K, Maeda N, Kikuchi K, Tatsukawa M, Sawayama Y, Hayashi J. Pravastatin improves insulin resistance in dyslipidemic patients. J Atheroscler Thromb 2005; 12: 322–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014; 63: 735.CrossRefPubMedGoogle Scholar
  18. 18.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011; 18: 1018–28.CrossRefPubMedGoogle Scholar
  19. 19.
    Botteridge DJ, Cannena R. The diabetogenic action of statins-mechanisms and clinical implications. Nat Rev Endocrinol 2016; 12: 99–110.Google Scholar
  20. 20.
    El-Bassiouni EA, Helmy MH, Abou Rawash N, El-Zoghby SM, Kamel MA-N, Abou Raya AN. Embryopathy in experimental diabetic gestation: assessment of oxidative stress and antioxidant defense. Br J Biomed Sci 2005; 62: 71–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Rosa MS, Pinto AM. Cytokines. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics, 4th ed.. St Louis: Elsevier Saunders, 2006, 645.Google Scholar
  22. 22.
    Burtis CA, Ashwood ER. Lipids, lipoproteins, apolipoproteins and others cardiovascular risk factors, prostaglandins. In: Bruns DE, ed. Tietz textbook of clinical chemistry and molecular diagnostics, 6th ed.. St Louis: Elsevier Saunders, 2008, 409.Google Scholar
  23. 23.
    Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.PubMedGoogle Scholar
  24. 24.
    Lim A, and Tesch G. Inflammation in diabetic nephropathy. Mediators of Inflammation 2012, 2012:Article ID 146154.Google Scholar
  25. 25.
    Mathey E, Pollard J, Armati P. In situ hybridization for cytokines in human tissue biopsies. Methods Mol Biol 249; 2004: 41–6.PubMedGoogle Scholar
  26. 26.
    Glocker EO, Kotlart D, Klein C, Shah N, Grimmbacher B. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci 2011; 1246: 102–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503–8.CrossRefPubMedGoogle Scholar
  28. 28.
    O’Neill LAJ. Toward an understanding of the signal transduction pathways for interleukin-1. Biochem Biophys Acta 1995; 1266: 31–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Henze B, Brune K. Cyclooxygenase-2: 10 years later. J Pharmacol Exper Therap 2002; 300: 367–75.CrossRefGoogle Scholar
  30. 30.
    Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986–1000.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Legler DF, Bruckne M, Uetz-vonAllemen E, Krause P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chance. Int J Biochem Cell Biol 2010; 42: 198–201.CrossRefPubMedGoogle Scholar

Copyright information

© John Libbey Eurotext 2016

Authors and Affiliations

  1. 1.Medical Analyses Department, Faculty of Pharmacy and Medical SciencesAl-Ahliyya Amman UniversityAmmanJordan

Personalised recommendations